Disease · MONDO_0018912

Cushing syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Cushing syndrome. Diseases, record MONDO_0018912. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018912

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Cushing syndrome; Open Targets
Open Targets ID: MONDO_0018912; Open Targets
Other names: Cushing's syndrome, Cushing's syndrome NOS, Cushing's syndrome NOS (disorder), cortisol Excess, hyperadrenocorticism, hypercorticism, pituitary basophilism, suprarenogenic syndrome; Open Targets
MeSH: D003480; MeSH
NCI Thesaurus: C2969; NCI Thesaurus
Orphanet: ORPHA:553; Orphanet
Highest stage of its drugs: Approval, for 5 of its 14 drugs, from DailyMed, EMA Human Drugs and PMDA; Open Targets

Drugs14

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OSILODROSTAT	CHEMBL3099695	Small molecule	Approval	EMA Human Drugs	7	6	6	Drugs and targets
MIFEPRISTONE	CHEMBL1276308	Small molecule	Approval	DailyMed	5	4	4	Drugs and targets
LEVOKETOCONAZOLE	CHEMBL295698	Small molecule	Approval	DailyMed	4	3	3	Drugs and targets
KETOCONAZOLE	CHEMBL157101	Small molecule	Approval	EMA Human Drugs	2	0	0	Drugs and targets
OSILODROSTAT PHOSPHATE	CHEMBL3707393	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
RELACORILANT	CHEMBL4068611	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
METYRAPONE	CHEMBL934	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ABIRATERONE ACETATE	CHEMBL271227	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CLOFUTRIBEN	CHEMBL5314513	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NEVANIMIBE HYDROCHLORIDE	CHEMBL542103	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 14

See all 14 drugs

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	5	Glucocorticoid receptor agonist; Glucocorticoid receptor antagonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
CYP11B1	Cytochrome P450 11B1, mitochondrial	4	Cytochrome P450 11B1 inhibitor; Cytochrome P450 11B1, mitochondrial inhibitor	Approval	https://conductscience.org/library/genes/1584	Drugs and targets
CYP17A1	Steroid 17-alpha-hydroxylase/17,20 lyase	2	Cytochrome P450 17A1 inhibitor	Approval	https://conductscience.org/library/genes/1586	Drugs and targets
CYP11A1	Cholesterol side-chain cleavage enzyme, mitochondrial	1	Cytochrome P450 11A1 inhibitor	Approval	https://conductscience.org/library/genes/1583	Drugs and targets
CYP11B2	Cytochrome P450 11B2, mitochondrial	1	Cytochrome P450 11B2 inhibitor	Approval	https://conductscience.org/library/genes/1585	Drugs and targets
PGR	Progesterone receptor	1	Progesterone receptor antagonist	Approval	https://conductscience.org/library/genes/5241	Drugs and targets

Trials20

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03697109	A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome	Phase 3	152	2025-04-24	Cushing Syndrome	RELACORILANT	Its record names the disease	ClinicalTrials.gov
NCT03606408	Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699	Phase 2	127	2024-12-18	Cushing's Syndrome	OSILODROSTAT	Its record names the disease	ClinicalTrials.gov
NCT05633953	Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome		103	2025-02-10	Cushing's Syndrome	OSILODROSTAT	Its record names the disease	ClinicalTrials.gov
NCT01838551	Treatment for Endogenous Cushing's Syndrome	Phase 3	94	2021-04-19	Endogenous Cushing's Syndrome	LEVOKETOCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03277690	A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.	Phase 3	84	2022-11-08	Endogenous Cushing's Syndrome	LEVOKETOCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03621280	Open-label Treatment in Cushing's Syndrome	Phase 3	51	2025-06-19	Cushing Syndrome, Cushing Disease	LEVOKETOCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00569582	A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome	Phase 3	50	2012-05-28	Cushing's Syndrome	MIFEPRISTONE	Its record names the disease	ClinicalTrials.gov
NCT02804750	Study to Evaluate CORT125134 in Participants With Cushing's Syndrome	Phase 2	35	2019-09-25	Cushing's Syndrome	RELACORILANT	Its record names the disease	ClinicalTrials.gov
NCT00936741	An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome	Phase 3	30	2014-04-02	Cushing's Syndrome	MIFEPRISTONE	Its record names the disease	ClinicalTrials.gov
NCT00422201	Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion	Phase 2	18	2013-10-14	Cushing's Syndrome	MIFEPRISTONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Levoketoconazole vs Placebo: Number of Subjects With Loss of Therapeutic Response to Levoketoconazole Upon Withdrawing to Placebo Compared With the Proportion of Subjects With Loss of Therapeutic Response Upon Continuing Treatment With Levoketoconazole.	9 of 22	21 of 22	44	NCT03277690	Trial comparisons
Group 1: Low-dose Group vs Group 2: High-dose Group: deaths from any cause	0 of 17	0 of 18	35	NCT02804750	Trial comparisons
Group 1: Low-dose Group vs Group 2: High-dose Group: Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events	3 of 17	7 of 18	35	NCT02804750	Trial comparisons
Group 1: Low-dose Group vs Group 2: High-dose Group: Percentage of Participants With One or More Adverse Events	15 of 17	18 of 18	35	NCT02804750	Trial comparisons
Group 1: Low-dose Group vs Group 2: High-dose Group: serious adverse events	0 of 17	4 of 18	35	NCT02804750	Trial comparisons
Relacorilant (RW Phase) vs Placebo (RW Phase): Number of Patients With Any Increase or Modification in Diabetes Medication During the RW Phase	1 of 7	0 of 8	15	NCT03697109	Trial comparisons

Papers from its trials25

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33216275	RESULT	1	PubMed
31542384	RESULT	1	PubMed
26353009	RESULT	1	PubMed
24268504	RESULT	1	PubMed
24210085	RESULT	1	PubMed
23470964	RESULT	1	PubMed
22997446	RESULT	1	PubMed
22466348	RESULT	1	PubMed
21612468	RESULT	1	PubMed
21220434	RESULT	1	PubMed

1 to 10 of 25

See all 25 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018912

GET https://conductscience.org/api/diseases/v1/MONDO_0018912/papers?page=2

API reference For AI assistants